SCHEMBL1905804

SCHEMBL1905804

Cc1cc(NCC(CI)c2cc[nH]c(=O)c2)nc(-c2cc(F)c(F)cc2F)n1

nearest known ligand 0.37

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 5/20 0.37
MEN1 O00255 2/20 0.32
ALDH1A1 P00352 2/20 0.32
HPGD P15428 2/20 0.32
KMT2A Q03164 2/20 0.32
HSD17B10 Q99714 2/20 0.32
MAPT P10636 3/20 0.31
KDM4E B2RXH2 2/20 0.31
LMNA P02545 1/20 0.31
GAA P10253 1/20 0.31
ALOX15 P16050 1/20 0.31
CASP1 P29466 1/20 0.31
HTT P42858 1/20 0.31
ATM Q13315 1/20 0.31
NPSR1 Q6W5P4 1/20 0.31
L3MBTL1 Q9Y468 1/20 0.31
RECQL P46063 1/20 0.30
USP1 O94782 1/20 0.30
WDR48 Q8TAF3 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL391957 0.87 CYP1A2 (0.38) CYP1A2MEN1ALDH1A1HPGDKMT2A
SCHEMBL391847 0.86 CYP1A2 (0.40) CYP1A2MEN1ALDH1A1HPGDKMT2A
SCHEMBL1904848 0.73 CYP1A2 (0.36) CYP1A2MEN1ALDH1A1HPGDKMT2A
SCHEMBL3691975 0.69 CYP1A2 (0.50) CYP1A2MEN1ALDH1A1HPGDKMT2A
SCHEMBL14403201 0.65 CYP1A2 (0.51) CYP1A2MEN1ALDH1A1HPGDKMT2A
SCHEMBL392408 0.64 CYP1A2 (0.54) CYP1A2MEN1ALDH1A1HPGDKMT2A
SCHEMBL8377531 0.62 CYP1A2 (0.56) CYP1A2MEN1ALDH1A1HPGDKMT2A
SCHEMBL391954 0.60 CYP1A2 (0.85) CYP1A2MEN1ALDH1A1HPGDKMT2A
SCHEMBL390010 0.59 CYP1A2 (0.53) CYP1A2
SCHEMBL386861 0.57 CYP1A2 (0.60) CYP1A2MEN1ALDH1A1HPGDKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2322157-A1 Composition for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood GLP-1 level Arena Pharmaceuticals, Inc. (US) 2011-05-18 EP disclosed